Neuronyx has taken a deliberate commercial approach to the use of cellular therapies initially focused on ischemic diseases. The company's scientists have identified and isolated a novel population of human adult bone marrow-derived somatic cells (hABM-SC) with the potential to treat a number of diseases because of their demonstrated ability to repair, regenerate and remodel damaged tissues in preclinical studies.
Our proprietary technology allows us to produce these cells efficiently and in large quantities for evaluation as medical therapies in numerous clinical applications.
1. Adult Derived — Neuronyx's human adult bone marrow-derived somatic cells (hABM-SC) are derived from a single, healthy volunteer human adult, obviating the ethical and political issues related to the use of embryonic and fetal stem cells.
2. Allogeneic — Allogeneic cell therapy (one product being delivered to many patients) is preferable to an autologous approach for several reasons. Autologous cell therapies are taken from a patient's own bone marrow, separated, expanded, and re-administered to the patient. Such therapies are commercially cumbersome given the cGMP resources that must be dedicated to developing each patient's own therapy and the time required to generate a therapeutic quantity of cells. Allogeneic therapies enable the production of large quantities of cells for therapeutic use from a single donor.
3. Efficient Production — Neuronyx has developed a robust manufacturing process that enables the production of sufficient quantities of cells from a single human donor to supply the entire predicted marketplace for a single indication. This means that the product that is tested in clinical trials is the same for every patient and is the same product that will eventually be sold. This represents a significant advantage over our competitors, who must use cells derived from dozens if not hundreds of discrete donors.
4. Non-immunogenic — Preclinical data suggest that hABM-SC are non-immunogenic.
5. Multiple Applications — The Company’s goal is to capitalize on the ability of hABM-SC to repair and remodel damaged tissue by using the same cell population for many disease indications and leveraging manufacturing efficiencies, preclinical safety data and clinical development to pursue multiple potential new indications. Our current focus is on the development of product for acute ischemic disease.
Neuronyx, Inc
1 Great Valley Parkway
Suite 20
Malvern, PA 19355
Tel: 610-240-4150
Fax: 610-240-4175
E-mail: info@neuronyx.com
